Eisai, Biogen continuing AD trial of BAN2401 despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to treat prodromal or mild Alzheimer’s disease. The partners said the study will

Read the full 479 word article

User Sign In